STAA and ALC Related Headlines
Go Back- Alcon terminates merger agreement with STAAR Surgical
- Alcon Terminates Agreement to Acquire STAAR Surgical
- Exclusive: STAAR Surgical deal fails as shareholder support remains at around 30%
- Broadwood Partners Comments on STAAR Surgical Shareholders’ Rejection of Proposed Sale to Alcon
- Broadwood Partners Comments on STAAR Surgical Shareholders’ Rejection of the Company’s Proposed Sale to Alcon
- Exclusive: STAAR merger with Alcon still fails to gain traction, only 30% vote for
- Broadwood criticizes STAAR Surgical's fourth delay of shareholder vote
- Broadwood Partners Denounces STAAR Surgical’s Fourth Delay of the Shareholder Vote on the Company’s Proposed Sale to Alcon
- Alcon exercises right to adjourn STAAR Surgical stockholder meeting
- Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders
- Broadwood sees $50/share path for STAAR Surgical as merger battle nears voting day
- Defender Capital opposes STAAR Surgical sale to Alcon ahead of vote
- Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc.
- Broadwood pledges cooperation with STAAR Surgical after Alcon deal vote
- Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails
- STAAR Surgical urges shareholders to approve Alcon's $30.75 per share offer
- STAAR Stockholders Have a Choice: Vote FOR Alcon’s Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value
- ISS recommends STAAR Surgical deal, but warns shareholders have reason to object
- Yunqi Capital opposes STAAR merger with Alcon despite revised offer
- Yunqi Capital Comments on Proxy Advisors’ Updated Recommendations, Urges Shareholders to Continue to Back the Company’s Standalone Trajectory
- STAAR Surgical gets analyst support for Alcon merger at $30.75 per share
- Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction
- Broadwood Partners opposes STAAR Surgical sale to Alcon amid proxy concerns
- Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon
- Leading Independent Proxy Advisory Firm ISS Recommends STAAR Stockholders Vote “FOR” Alcon Merger
- Glass Lewis reaffirms opposition to STAAR Surgical sale to Alcon
- Broadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation “AGAINST” STAAR Surgical Sale to Alcon
- STAAR Surgical defends merger process amid activist criticism
- STAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process
- Broadwood opposes revised STAAR Surgical-Alcon deal, cites board dissent
- Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon
- STAAR Surgical falls as Yunqi Capital reiterates opposition to merger with Alcon
- Yunqi Capital opposes STAAR Surgical merger despite Alcon's raised bid
- Yunqi Capital Comments on STAAR Surgical’s Go-Shop Process and Alcon’s Revised Offer
- Alcon bumps STAAR Surgical bid to $30.75, but Broadwood remains vehemently against
- Broadwood opposes revised STAAR Surgical acquisition by Alcon
- Broadwood Partners Responds to Alcon’s Increase to Proposed Acquisition Price of STAAR Surgical
- Alcon raises STAAR acquisition price to $30.75 per share
- Alcon Announces Amended Merger Agreement with STAAR Surgical
- Broadwood Partners maintains opposition to STAAR Surgical sale to Alcon
- Broadwood Partners Reiterates Opposition to STAAR Surgical’s Sale to Alcon Following Conclusion of Performative Go-Shop Process
- Egan-Jones reaffirms vote against STAAR Surgical sale to Alcon
- Broadwood Partners: Proxy Advisory Firm Egan-Jones Reaffirms Its Recommendation STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon
- STAAR Surgical's go-shop period expires with no competing bids
- STAAR Surgical Announces Expiration of Go-Shop Period
- Broadwood reiterates push for STAAR Surgical board shake-up as Alcon vote nears
- Broadwood Partners seeks to remove three STAAR Surgical directors
- Broadwood Partners Working to Call Special Meeting of STAAR Surgical Shareholders to Remove Three Directors
- STAAR Surgical reveals board dissent over amended Alcon deal ahead of vote
- Exclusive: Broadwood says Alcon's earnings reveal STAAR bid came from 'weakness'
- Broadwood calls for new directors at STAAR Surgical for go-shop oversight
- Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process
- STAAR Surgical amends Alcon merger deal to allow 30-day bidding period
- STAAR Surgical Announces Amendments to Alcon Merger Agreement
- Yunqi Capital urges STAAR shareholders to reject Alcon merger after Q3 results
- Yunqi Capital Applauds STAAR Surgical’s Strong Third Quarter Results and Reiterates That the Proposed Sale to Alcon Should Be Terminated
- Alcon, Broadwood trade blows in fight for STAAR Surgical's future
- Broadwood opposes Alcon's STAAR Surgical acquisition bid
- Broadwood Partners Condemns Alcon’s Fallacious Attacks on STAAR Surgical and Its Prospects
- Alcon Releases Investor Discussion Materials Reinforcing Certain Value of Merger Proposal for STAAR Stockholders
STAA and ALC Related Press Releases
Go Back- Alcon Terminates Agreement to Acquire STAAR Surgical
- Broadwood Partners Comments on STAAR Surgical Shareholders’ Rejection of the Company’s Proposed Sale to Alcon
- Broadwood Partners Denounces STAAR Surgical’s Fourth Delay of the Shareholder Vote on the Company’s Proposed Sale to Alcon
- Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders
- Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc.
- Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails
- STAAR Stockholders Have a Choice: Vote FOR Alcon’s Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value
- Yunqi Capital Comments on Proxy Advisors’ Updated Recommendations, Urges Shareholders to Continue to Back the Company’s Standalone Trajectory
- Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction
- Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon
- Leading Independent Proxy Advisory Firm ISS Recommends STAAR Stockholders Vote “FOR” Alcon Merger
- Broadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation “AGAINST” STAAR Surgical Sale to Alcon
- STAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process
- Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon
- Yunqi Capital Comments on STAAR Surgical’s Go-Shop Process and Alcon’s Revised Offer
- Broadwood Partners Responds to Alcon’s Increase to Proposed Acquisition Price of STAAR Surgical
- Alcon Announces Amended Merger Agreement with STAAR Surgical
- Broadwood Partners Reiterates Opposition to STAAR Surgical’s Sale to Alcon Following Conclusion of Performative Go-Shop Process
- Broadwood Partners: Proxy Advisory Firm Egan-Jones Reaffirms Its Recommendation STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon
- STAAR Surgical Announces Expiration of Go-Shop Period
- Broadwood Partners Working to Call Special Meeting of STAAR Surgical Shareholders to Remove Three Directors
- Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process
- STAAR Surgical Announces Amendments to Alcon Merger Agreement
- Yunqi Capital Applauds STAAR Surgical’s Strong Third Quarter Results and Reiterates That the Proposed Sale to Alcon Should Be Terminated
- Broadwood Partners Condemns Alcon’s Fallacious Attacks on STAAR Surgical and Its Prospects
- Alcon Releases Investor Discussion Materials Reinforcing Certain Value of Merger Proposal for STAAR Stockholders
